RALOXIFENE
READ ALL AT
http://www.genericsweb.com/newsletter.html
May 302013
Predicting Drug Toxicity in Humans
TOXICITY
Comments Off on Predicting Drug Toxicity in Humans
May 302013
Predicting Drug Toxicity in Humans
Genetic Engineering News
“A major challenge of drug safety testing is that preclinical studies with laboratory animals are not always predictive of human safety,” said Albert P. Li, Ph.D., president and CEO of In Vitro ADMET Laboratories. Dr. Li cited the frequent clinical ………………………….http://www.genengnews.com/gen-articles/predicting-drug-toxicity-in-humans/4815/
Encouraging Data from Alkermes, ALKS 3831 – Analyst Blog
drugs
Comments Off on Encouraging Data from Alkermes, ALKS 3831 – Analyst Blog
May 302013
NASDAQ
Data was presented at the 53rd annual meeting of the New Clinical Drug Evaluation Unit (NCDEU) held in the US. ALKS 3831 … Encouraged by the positive results of the phase I study, Alkermes expects to initiate a phase II dose-ranging study on ALKS 3831.http://www.nasdaq.com/article/encouraging-data-from-alkermes-analyst-blog-cm249504
Alkermes plc recently presented encouraging data from a phase I study, which evaluated its schizophrenia candidate, ALKS 3831. Data was presented at the 53rd annual meeting of the New Clinical Drug Evaluation Unit (NCDEU) held in the US. ALKS 3831 is a combination of ALKS 33, and Eli Lilly and Company’ s antipsychotic drug Zyprexa (olanzapine).
A Fundamental Take On Alkermes’ Turnaround Story
drugs
Comments Off on A Fundamental Take On Alkermes’ Turnaround Story
May 302013
A Fundamental Take On Alkermes’ Turnaround Story
Seeking Alpha
These products are for multiple sclerosis complication, Opioid dependence, alcohol dependence, schizophrenia and Type 2 diabetes. The drugs are in the early phase of the product cycle, and hence the possibility of faster growth in revenues is …http://seekingalpha.com/article/1467401-a-fundamental-take-on-alkermes-turnaround-story?source=google_news
The product pipeline consists of drugs like ZOHYDRO ER (pain) for which patent has been filed, and other drug candidates like Exenatide (Type 2 diabetes), Aripiprazole Lauroxil (schizophrenia), INVEGA SUSTENNA (schizophrenia), ALKS 5461 (major depressive disorder), and ALKS 3831 (schizophrenia), which are in phase 2/phase 3 of trial.
Silence Starts Phase Ia/IIb Trial of Cancer Drug as It Looks to Balance Pipeline
cancer
Comments Off on Silence Starts Phase Ia/IIb Trial of Cancer Drug as It Looks to Balance Pipeline
May 302013
Silence Starts Phase Ia/IIb Trial of Cancer Drug as It Looks to Balance Pipeline
Silence Starts Phase Ia/IIb Trial of Cancer Drug as It Looks to Balance Pipeline GenomeWeb If no toxicity is observed, the phase IIa arm of the trial will begin with pancreatic cancer patients receiving the two drugs once a week for three consecutive weeks, with no treatment on the fourth week. This dosing schedule will continue in … http://www.genomeweb.com/rnai/silence-starts-phase-iaiib-trial-cancer-drug-it-looks-balance-pipeline
May 292013
3 Biopharma Runners With Fuel in the Tank
Investorplace.com
Gilead Sciences (GILD) stock recently set a new all-time high after reporting that in a recent Phase 2 study, its oral drug idelalisib successfully drove the life-threatening chronic lymphocytic leukemia (CLL) into remission. The regimen produced a 97% …
Gilead Sciences (GILD) stock recently set a new all-time high after reporting that in a recent Phase 2 study, its oral drug idelalisib successfully drove the life-threatening chronic lymphocytic leukemia (CLL) into remission. The regimen produced a 97% response rate, with 93% of trial patients surviving progression-free at the end of two years. CLL, which produces too many mature white cells, is the second most common form of leukemia in the U.S.
http://investorplace.com/2013/05/3-biopharma-runners-with-fuel-in-the-tank/
May 282013
EPFL scientists have revealed the mechanism, hidden deep within cell mitochondria, that is responsible for making organisms age. Nematodes treated with antibiotics designed to disrupt this mechanism lived longer and healthier lives.
(Photo Credit: EPFLnews)
Slowing the aging process using only antibiotics
READ ALL AT
| Why is it that within a homogeneous population of the same species, some individuals live three times as long as others? EPFL researchers investigated this question and found the mechanism responsible for aging hidden deep within mitochondria. The were able to dramatically slow aging down in worms by administering antibiotics to the young, achieving a … more… |
Merrimack-completes-patient-enrollment-in-phase-2-breast-cancer-study
drugs
Comments Off on Merrimack-completes-patient-enrollment-in-phase-2-breast-cancer-study
May 282013
Diabetes Drug To Be Sold As Weight Loss Medication Liraglutide (Victoza),
drugs
Comments Off on Diabetes Drug To Be Sold As Weight Loss Medication Liraglutide (Victoza),
May 282013
liraglutide
Read all at 
http://www.medicaldaily.com/articles/15910/20130526/diabetes-drug-sold-weight-loss-medication.htm
Danish pharmaceutical company Novo Nordisk announced plans to re-brand and sell its diabetes drug liraglutide (Victoza) as a weight loss drug for obese people by 2015. Currently, the drug is approved and sold to help regulate insulin production in people living with type 2 diabetes.
Rapamycin Holdings Hopes To Exploit Commercial Potential Of UT Health Science Center Anti-Aging Drug Research
phase 1
Comments Off on Rapamycin Holdings Hopes To Exploit Commercial Potential Of UT Health Science Center Anti-Aging Drug Research
May 282013
Sirolimus (INN/USAN), also known as rapamycin, is an immunosuppressant drug used to prevent rejection in organ transplantation; it is especially useful in kidney transplants. It prevents activation of T cells and B cells by inhibiting their response to interleukin-2 (IL-2). Sirolimus is also used as a coronary stent coating.
A macrolide, sirolimus was discovered by Brazilian researchers as a product of the bacterium Streptomyces hygroscopicus in a soil sample from Easter Island — an island also known as Rapa Nui. It was approved by the FDA in September 1999 and is marketed under the trade name Rapamune by Pfizer (formerly by Wyeth).
Sirolimus was originally developed as an antifungal agent. However, this use was abandoned when it was discovered to have potent immunosuppressive and antiproliferative properties. It has since been shown to prolong the life of mice and might also be useful in the treatment of certain cancers.
Rapamycin Holdings Hopes To Exploit Commercial Potential Of UT Health …
BioNews Texas
Rapamycin Holdings will be looking to raise an additional $6 million as it approaches the point of taking its first drug product to Phase 1 clinical trials. On December 7, 2012, Rapamycin Holdings Chief Executive Officer George Fillis announced that …
read all at
